Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares Outstanding
Ratios

Keros Therapeutics (KROS) Accumulated Depreciation & Amortization: 2019-2024

  • Keros Therapeutics' Accumulated Depreciation & Amortization rose 71.45% to $2.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was $6.7 million, marking a year-over-year increase of 50.07%. This contributed to the annual value of $2.9 million for FY2024, which is 71.45% up from last year.
  • Latest data reveals that Keros Therapeutics reported Accumulated Depreciation & Amortization of $2.9 million as of Q4 2024, which was up 71.45% from $1.7 million recorded in Q4 2023.
  • Keros Therapeutics' 5-year Accumulated Depreciation & Amortization high stood at $2.9 million for Q4 2024, and its period low was $721,000 during Q4 2020.
  • For the 3-year period, Keros Therapeutics' Accumulated Depreciation & Amortization averaged around $1.9 million, with its median value being $1.7 million (2023).
  • Data for Keros Therapeutics' Accumulated Depreciation & Amortization shows a peak YoY skyrocketed of 71.45% (in 2024) over the last 5 years.
  • Quarterly analysis of 5 years shows Keros Therapeutics' Accumulated Depreciation & Amortization stood at $721,000 in 2020, then climbed by 17.34% to $846,000 in 2021, then skyrocketed by 37.47% to $1.2 million in 2022, then surged by 47.89% to $1.7 million in 2023, then surged by 71.45% to $2.9 million in 2024.
  • Its Accumulated Depreciation & Amortization stands at $2.9 million for Q4 2024, versus $1.7 million for Q4 2023 and $1.2 million for Q4 2022.